GW Pharmaceuticals Plc (GWPH)

165.46
0.55 0.33
NASDAQ : Health Technology
Prev Close 166.01
Open 167.36
Day Low/High 164.07 / 167.99
52 Wk Low/High 90.14 / 196.00
Volume 289.89K
Avg Volume 360.80K
Exchange NASDAQ
Shares Outstanding 30.72M
Market Cap 5.10B
EPS -9.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Some Cannabis Stocks Rise as DEA Rethinks CBD Stance

Some Cannabis Stocks Rise as DEA Rethinks CBD Stance

The DEA will now classify certain drug products to containing cannabidiol as schedule V.

Legalized Recreational Marijuana Won't Kill Medical Marijuana

Legalized Recreational Marijuana Won't Kill Medical Marijuana

Sales trends and the potential for stronger versions of prescription cannabis offer medical marijuana providers hope.

CBD Doesn't Get You High, But Could Someday Eclipse the Entire Pot Industry

CBD Doesn't Get You High, But Could Someday Eclipse the Entire Pot Industry

Cannabidiol, or CBD, is a cannabis extract that's used to treat everything from pain to opiate addiction to PTSD. It doesn't get you high -- but advocates say that's the reason that CBD could soon eclipse the multibillion-dollar pot industry.

History of Marijuana: Origins, Legality and What's Happening in 2018

History of Marijuana: Origins, Legality and What's Happening in 2018

Marijuana has gone from an ancient medicinal herb to an edible gummy bear -- but how has the plant's tumultuous past impacted its future market?

GW Pharmaceuticals Reaches Analyst Target Price

GW Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of GW Pharmaceuticals plc have crossed above the average analyst 12-month target price of $168.88, changing hands for $170.10/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Insys Therapeutics Is a Pretend Cannabis Stock

Insys Therapeutics Is a Pretend Cannabis Stock

It is time for investors to start differentiating between the Good, the Bad and the Ugly in cannabis stocks.

What is THC? Experts Weigh in on Benefits and Effects

What is THC? Experts Weigh in on Benefits and Effects

THC is the psychoactive ingredient in marijuana that produces the feeling of being high. But, THC also has other applications that include health benefits and some side effects.

5 Big Biotech Stories to Watch

5 Big Biotech Stories to Watch

The biotech and pharmaceutical industries have had some big news in recent weeks. Here's what you should know to stay up-to-date.

FDA Approval Of GW Pharma's Cannabis-Based Drug Marks Milestone

FDA Approval Of GW Pharma's Cannabis-Based Drug Marks Milestone

Approval of epilepsy drug using the marijuana derivative CBD is the first time the FDA has sanctioned medical use of cannabidiol.

FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

The milestone approval of Epidiolex bodes well for cannabis-based drug stocks GW Pharma, Nemus, Zynerba and Insys.

DocuSign, DexCom, Skechers USA: 'Mad Money' Lightning Round

DocuSign, DexCom, Skechers USA: 'Mad Money' Lightning Round

Jim Cramer weighs in on DocuSign, DexCom, Skechers USA, Campbell Soup, Evolus, Zscaler, Lockheed Martin and more.

Revaluing Entertainment Companies: Cramer's 'Mad Money' Recap (Thursday 6/14/18)

Revaluing Entertainment Companies: Cramer's 'Mad Money' Recap (Thursday 6/14/18)

Jim Cramer says there's the market that's about entertainment and anything that delivers entertainment to you. And then there's everything else.

Seven U.S. Stocks Offering Cannabis Exposure

Seven U.S. Stocks Offering Cannabis Exposure

While cannabis remains illegal on a federal level, these seven names are making early inroads into the growing industry.

Jim Cramer: These 4 Cold Stocks of Once-Hot Companies Could Reignite

Jim Cramer: These 4 Cold Stocks of Once-Hot Companies Could Reignite

It's important to know the difference between broken stocks and broken companies.

Snap, Costco, Seagate Technology: 'Mad Money' Lightning Round

Snap, Costco, Seagate Technology: 'Mad Money' Lightning Round

Jim Cramer shines a spotlight on Snap, Costco, Seagate Technology, GW Pharmaceuticals, Danaher, General Mills and more.

Haters Gonna Hate: Cramer's 'Mad Money' Recap (Wednesday 5/2/18)

Haters Gonna Hate: Cramer's 'Mad Money' Recap (Wednesday 5/2/18)

We have a wall of worry to overcome, but it's important to hear the other side of the trade, says Jim Cramer. Take Apple and Facebook, for example.

Cannabis Industry Sits on Precipice of Major Expansion

Cannabis Industry Sits on Precipice of Major Expansion

A string of good news for the cannabis sector may prompt institutional investors to get into the game, but watch valuations increase.

Not Thankful for Fridays: Cramer's 'Mad Money' Recap (Friday 4/20/18)

Not Thankful for Fridays: Cramer's 'Mad Money' Recap (Friday 4/20/18)

Jim Cramer says analysts and trade woes put a damper on buying ahead of the weekend. So let's get the game plan for next week.

The Market Is Finally Rewarding Stock Picking

The Market Is Finally Rewarding Stock Picking

The game plan is to spot the charts that have more room to run.

American Electric Power, Fifth Third Bancorp: 'Mad Money' Lightning Round

American Electric Power, Fifth Third Bancorp: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at American Electric Power, Fifth Third Bancorp, Applied Materials, EPR Properties, GW Pharmaceuticals and Longfin.

With Nothing to Buy, Everyone Sells: Cramer's 'Mad Money' Recap (Thur 3/22/18)

With Nothing to Buy, Everyone Sells: Cramer's 'Mad Money' Recap (Thur 3/22/18)

Jim Cramer calls it a tsunami of selling. Not one sector of the stock market got a break in Thursday's tariff-inspired decline.

GW Pharmaceuticals Announces The European Medicines Agency (EMA) Accepts Epidiolex® (cannabidiol) Marketing Authorization Application (MAA) For Review

GW Pharmaceuticals Announces The European Medicines Agency (EMA) Accepts Epidiolex® (cannabidiol) Marketing Authorization Application (MAA) For Review

MAA seeking regulatory approval of Epidiolex for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome